Business
Spectral Appoints Vice President of Sales and Marketing
TORONTO, May 7, 2013 /CNW/ - Spectral Diagnostics Inc., (TSX:SDI / OTCQX: DIAGF) , a Phase...
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n\n\nTORONTO, May 7, 2013 /CNW/ - Spectral Diagnostics Inc., (TSX:SDI / OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for\n patients with septic shock, today announced the appointment of  Dr.\n Gualtiero Guadagni as the Company's Vice President, Sales and\n Marketing.\n\n\nDr. Guadagni will primarily be responsible for the development and\n expansion of commercial opportunities for Toraymyxin and Spectral's\n Endotoxin Activity Assay (EAA™) in Canada, the United States and\n Europe.\n\n\n\"We are very excited to add Dr. Guadagni to the Spectral team at this\n stage of our clinical development plan for EAA and Toraymyxin.\" said\n Dr. Paul Walker, President and CEO of Spectral Diagnostics. \"Dr.\n Guadagni has extensive experience in market development and sales of\n the EAA and Toraymyxin theranostic approach to the management of septic\n shock in regions outside of North America.\"\n\n\nPrior to joining Spectral, Dr. Guadagni spent 10 years at ESTOR S.P.A\n where he was the company's sales and marketing director, and scientific\n consultant for Toraymyxin. ESTOR is a Milano-based company specialized\n in the production, promotion and sale of advanced biomedical devices in\n the areas of dialysis, intensive care and hemodynamics.\n\n\nAs ESTOR's European sales and marketing director, Dr. Guadagni managed\n an 18-person sales team that focussed on selling and marketing\n Toraymyxin and EAA in Italy, Switzerland and Austria where the sales of\n EAA and Toraymyxin have grown annually.\n\n\nAs a scientific consultant for ESTOR, he coordinated a number of\n post-marketing clinical trials such as the \"Euphas\" trial (Early Use of\n Polymyxin B Hemoperfusion In Abdominal septic Shock). In 2010, he\n coordinated Euphas2 (www.euphas2.eu), an international data registry for Toraymyxin and EAA use in\n critically ill patients with septic shock, in multiple countries\n worldwide.\n\n\nDr. Guadagni has a PhD in bioengineering and a master's degree in\n biomedical engineering, both from Politecnico di Milano University in\n Italy.\n\n\nSpectral's EUPHRATES trial second planned interim analysis will occur\n after 184 randomized patients have been followed for 28 days. At the\n second analysis, the trial's Data and Safety Monitoring Board (DSMB)\n will advise Spectral on the trial's safety, ef...